Psychedelic Safety & Research

Three Infusions in Twelve Weeks: A Toronto Pain Trial Ran a Very Different Protocol

A Toronto trial paired ketamine with structured therapy for chronic nerve pain. It used three infusions over twelve weeks, not six over three.

There Are Now Clinics for People Harmed by Psychedelics. Here Is Where They Are

Johns Hopkins opened the first US clinic for lasting psychedelic side effects. Where the clinics are, what they treat, what recovery looks like, and what to do meanwhile.

A Meditation Retreat Produced Psychedelic-Like Brain Changes. Here Is What the Study Actually Shows

A study is circulating with a striking claim. Seven days at a meditation retreat, no drugs involved, and participants’ brains showed connectivity patterns resembling those seen under psychedelics. The measurements are real. Nearly every headline about them is describing something the study did not do. New competition is a margin problem before it is a […]

An Oral LSD Tablet Has Now Cleared Phase 3 Twice This Year. Here Is What Comes Next

Editor’s note (September 16, 2026): DT120 has since cleared a third Phase 3 trial. We covered the Panorama results and the low-dose arm designed to address unblinding. An oral LSD tablet has now cleared phase 3 twice in a single year. Definium Therapeutics reported that DT120 ODT met its primary endpoint in generalized anxiety disorder, […]

MAPS-Funded MDMA Therapy for PTSD Is Back at the FDA, Without a New Phase 3 Trial

MDMA assisted therapy for PTSD appears to be back in front of the FDA. Psychedelic Alpha reported on August 9 that Resilient Pharmaceuticals has resubmitted the application the agency declined two years ago. MAPS responded to that report the next day without independently confirming it. The detail that matters is not the resubmission. It is […]

Psilocybin Sessions for PTSD Are Mostly Silent. The Argument About What to Call Them Is Not

A new analysis found psilocybin dosing sessions for PTSD are silent 78 percent of the time. Why the authors want the name changed, and who benefits if it is.

Ketamine Raised Morning Cortisol in a New Trial. Here Is What That Might Mean

A randomized trial found higher morning cortisol 24 hours after ketamine. Bigger rises tracked with less suicidal thinking, though more data needed.

Why Some Psychedelic Sessions Turn Frightening. A New Brain Study Offers a Clue

Most people who take a psychedelic under clinical supervision come through the session well. Some do not. A 2026 Stanford study in the Proceedings of the National Academy of Sciences offers a partial explanation for that difference. The clue sits in an unexpected place, namely the direction brain signals travel. Do you work in the […]

New Research Links Your Immune System to Depression Relief

Researchers found that these therapies change how the immune system talks to the brain. The work appeared in the journal Molecular Psychiatry.

Nine of 12 Veterans Reached PTSD Remission After Psilocybin Therapy in Small Study

A small clinical trial found striking improvements among veterans with severe post traumatic stress disorder that had resisted standard care. Nine of 12 participants no longer met PTSD criteria one month after psilocybin assisted therapy. The result offers an important signal, but the study cannot prove that the treatment caused the improvement. Looking for treatment? Find Spravato clinics […]